Regulatory lnflexibility May Require UniQure To Conduct Sham Surgery
The FDA has reiterated its request for a sham surgery-controlled, Phase III trial of uniQure’s gene therapy candidate for Huntington’s disease, an idea some call unethical.
Scrip - March 2, 2026

Venture Funding Still Difficult For Early Start-Ups, But There Are Some Green Shoots
Panelists at BIO’s Investor and Growth Summit described a tough funding environment for early-stage companies, but identified some emerging opportunities for start-ups.
Scrip - March 2, 2026

Novartis Forges Ahead With Rhapsido For Food Allergy
The Swiss major's immunology chief Angelika Jahreis tells Scrip of her high hopes for the potential pipeline-in-a-product.
Scrip - March 2, 2026

Deaths Cast Shadow Over Fenebrutinib’s Phase III Multiple Sclerosis Success
Roche believes its drug has a strong benefit-risk profile but analysts think the eight trial deaths could see it rejected, just like Sanofi’s rival BTK inhibitor.
Scrip - March 2, 2026

Ascendis Wins FDA Nod For Weekly Achondroplasia Therapy Yuviwel, Eyes Q2 US Launch
Ascendis Pharma’s accelerated US approval of once-weekly Yuviwel introduces the first competitor to BioMarin’s Voxzogo in achondroplasia, setting up a dosing-driven competitive dynamic in the CNP segment.
Scrip - March 2, 2026

Aardvark’s PWS Trial Pause Raises Questions On Safety Edge For Appetite Suppressor
Aardvark’s pause of its Phase III PWS trial after a cardiac signal in a separate study has shaken confidence in the drug’s once?touted safety edge and has triggered a sharp fall in shares.
Scrip - March 2, 2026

Pipeline Watch: Eight Approvals And Three Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - March 2, 2026

China Approves Sino Biopharm’s First-In-Class Oral Molecule For 1L Myelofibrosis
China’s National Medical Products Administration grants global-first approval to oral JAK/ROCK inhibitor for adult primary and secondary myelofibrosis.
Scrip - March 2, 2026

Asahi Kasei Grows Pharma Business Via M&A With Niche-Focused Strategy
The Japanese industrial material group expands its global presence with a strategic niche focus on immunology, organ transplantation, and severe infectious diseases.
Scrip - March 2, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Zealand CEO calls for end to 'weight loss Olympics'; MSD on AI-assisted pipelines; Bruce Levine’s CAR-T stories; biopharma dealmaking bounces back; and 2025 was a tough year for US IPOs.
Scrip - March 2, 2026

What Does Big Pharma Want From CRDMOs As AI Changes Rules?
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
Scrip - March 2, 2026

Systemic Issue Of Surgeon Burnout Focus Of Johnson & Johnson Report
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
Medtech Insight - March 2, 2026

Stakeholders Ask CMS For Additional TAVR Indications
CMS has reopened the TAVR coverage memo to consider coverage for without symptoms aortic stenosis and pure regurgitation. Stakeholders want to relax CED requirements and update NCD to include newer FDA-approved TAVR devices, improving patient access and outcomes in valvular heart disease treatment.
Medtech Insight - March 2, 2026

CMS Fraud Crackdown, Part 1: Six-Month Enrollment Ban On Some Durable Medical Equipment Suppliers
The Trump administration says a six-month moratorium on enrolling new suppliers of durable medical equipment is part of a wider strategy to combat healthcare fraud and abuse.
Medtech Insight - March 2, 2026

PDUFA VIII Negotiators Reach ‘Impasse’ On America First Proposal
Industry continues to oppose domestic manufacturing incentives that the FDA wants to include in the PDUFA reauthorization.
HBW Insight - March 3, 2026

Aveda Refillable Packaging Will Merge Sustainability, Functionality
The Estee Lauder Companies, Inc.’s Aveda brand is partnering with packaging tech firm AeroFlexx LLC to develop refillable packaging for ‘select best-selling’ products.
HBW Insight - March 3, 2026

First EU Pertuzumab Leads Latest EMA Biosimilar Nods
At its February meeting, the EMA’s CHMP issued positive opinions for six biosimilars – including the first rival to Perjeta.
Generics Bulletin - March 2, 2026

SamChunDang Seals Semaglutide Oral Generics Deal Across European Markets
SamChunDang Pharmaceutical has penned an exclusive licensing and commercialization agreement covering generic versions of oral semaglutide products in the UK and additional European markets.
Generics Bulletin - March 2, 2026

Viatris To Cut Around 3,000 Jobs Under $650m Savings Plan
Viatris will cut up to 10% of its global workforce – around 3,000 jobs – as part of a three-year restructuring plan targeting $650m in gross savings, with $250m set for reinvestment to boost growth and innovation, yielding roughly $400m in net savings by 2029.
Generics Bulletin - March 2, 2026

Podcast: Discussing The AAM’s Access! 2026 Conference With Pink Sheet
Generics Bulletin editor Dave Wallace joins Pink Sheet editors to discuss the generics and biosimilars industries’ priorities following the recent AAM Access! 2026 conference, as well as FDA Commissioner Martin Makary’s interesting take on the compassionate use program.
Generics Bulletin - March 2, 2026

‘This Can Be Weaponized’ – Sandoz Sounds Alarm Over Cheap Chinese Antibiotics
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
In Vivo - March 2, 2026

J&J Report Spotlights The Systemic Issue Of Surgeon Burnout
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
In Vivo - March 2, 2026